InMode Ltd. Provides Earnings Guidance for Q3 and Reaffirms Full-Year 2025 Guidance

InMode Ltd. has provided earnings guidance for Q3 2025, reaffirming its full-year 2025 guidance. The company's super rating is based on a weighted average of Global Valuation, EPS Revisions, and Visibility ratings. InMode Ltd. also received a quality composite rating, which is an average of Capital Efficiency, Quality of Financial Reporting, and Financial Health ratings.

InMode Ltd., a global provider of energy-based, minimally-invasive surgical medical treatment solutions, has provided earnings guidance for the third quarter of 2025. The company expects revenue for the period to be in the range of $92.5 million to $93.0 million. Additionally, InMode Ltd. has reaffirmed its full-year 2025 earnings guidance, projecting revenue to be between $365 million and $375 million InMode Ltd. Provides Earnings Guidance for the Third Quarter and Reaffirms Earnings Guidance Full Year 2025^[1].

InMode Ltd. operates in three primary energy-based treatment categories: face and body contouring, medical aesthetics, and women's health. The company's proprietary technologies, such as Radio Frequency Assisted Lipolysis (RFAL) and Deep Subdermal Fractional RF, have been developed to penetrate deep into the subdermal fat, allowing for adipose tissue remodeling. These technologies represent a paradigm shift in the minimally-invasive aesthetic solutions market InMode Ltd. Provides Earnings Guidance for the Third Quarter and Reaffirms Earnings Guidance Full Year 2025^[1].

The company's super rating is based on a weighted average of Global Valuation, EPS Revisions, and Visibility ratings. InMode Ltd. also received a quality composite rating, which is an average of Capital Efficiency, Quality of Financial Reporting, and Financial Health ratings. These ratings reflect the company's strong financial health and the quality of its financial reporting InMode Ltd. Provides Earnings Guidance for the Third Quarter and Reaffirms Earnings Guidance Full Year 2025^[1].

As of the current date, InMode Ltd. continues to demonstrate robust financial performance and a commitment to innovation in the medical aesthetics market. Investors and financial professionals should closely monitor the company's progress as it works towards achieving its revenue targets for the third quarter and full year 2025.